A unique collection of 104 compounds with defined hematopoietic toxicity for high throughput and high content drug screening; Safety and effectiveness of the small molecules have been demonstrated through preclinical and clinical research; Targets include HDAC, PPAR, DNA Alkylating, EGFR, etc.; Detailed compound information with structure, target, activity, IC50 value, and biological activity description; Structurally diverse, medicinally active, and cell permeable; NMR and HPLC validated to ensure high purity and quality;
